

## **WHO/MPP mRNA Technology Transfer Programme Follow-up regional meeting in South-East Asia – Establishing R&D consortia**

Sheraton Towers, 39 Scotts Road, 228230 Singapore  
Room: “Ballroom 2”  
Republic of Singapore  
18-19 March 2024

### **Agenda**

#### **Background**

Based on the outcomes of the WHO/MPP mRNA regional R&D meeting, held 31 October-1 November 2023 in Bangkok, Kingdom of Thailand, WHO and MPP are looking to establish the following research consortia to advance mRNA vaccine development up to proof of concept:

- A consortium on dengue mRNA vaccine product development to be led by the International Vaccine Institute (IVI), in collaboration with Chula VRC, Chulalongkorn University and mRNA manufacturing partners from Bangladesh and Indonesia.
- A consortium on hand, foot and mouth disease (HFMD) mRNA product development to be led by Hilleman labs in collaboration with Chula VRC, Chulalongkorn University, National University of Singapore and mRNA manufacturing partners from Vietnam.
- A consortium on therapeutic human papillomavirus (HPV) mRNA product development to be led initially by Chula VRC, Chulalongkorn University.
- A consortium on plasmodium vivax malaria mRNA product development to be led by Mahidol University in collaboration with Chula VRC, Chulalongkorn University.

**Objectives of the meeting** - The proposed objectives are to:

- 1) Review key scientific and technical considerations for mRNA vaccine development against dengue, HFMD, P. vivax and therapeutic HPV.
- 2) Discuss key roles and responsibilities of partners engaged in proposed consortia to advance mRNA vaccine development up to proof of concept early phase clinical development.
- 3) For each of the disease, discuss terms of MoU that will form the basis of the R&D consortia.
- 4) Discuss investment opportunities to support regional R&D collaboration.

## AGENDA

Monday 18 March 2024

Time	Topic	Speaker
8:30 – 9:00	Registration	
	General Objectives General principles and access considerations for R&D consortia 5 min	WHO / Hilleman Labs Pierre Gsell, WHO
<b>Part I – Establishing a mRNA R&amp;D consortia for dengue</b>		
9:30 – 12:30	Welcome and introduction – 5 min  Summary of key scientific and technical considerations to advance dengue vaccine development – 30 min  Draft Target Product Profile for a mRNA dengue vaccine, 20 min  Preclinical development update of a mRNA candidate vaccine, 10 min  Coffee Break, 30 min  Consortia proposal and discussion – 1 hr 30 min <ul style="list-style-type: none"> <li>- Definition of consortia goal</li> <li>- Timelines and Budget proposal</li> <li>- Gantt Chart</li> <li>- List of members</li> <li>- Roles and Responsibilities</li> <li>- Stakeholder engagement</li> </ul>	Jerome Kim, IVI  Ooi Eng Eong, Duke-NUS Medical School  Hee Soo Kim, IVI  Chutitorn Ketloy, Chula VRC  Moderated by Sushant Sahastrabudde, IVI  Panellists - Jerome Kim, Hee Soo Kim and Manki Song, IVI In-Kyu Yoon, CEPI Kiat Ruxrungtham, Chula VRC Nakorn Preamsri, NVI
12.30 – 14.00	<i>Lunch</i>	
<b>Part I – Establishing a mRNA R&amp;D consortia for <i>P. vivax</i> malaria</b>		
14:00– 17:00	Summary of key scientific and technical considerations to advance therapeutic <i>P. vivax</i> malaria vaccine development, 15 min  Establishment of human challenge model for <i>P. vivax</i> , 15 min  Draft Target Product Profile for a mRNA <i>P. vivax</i> malaria vaccine, 15 min  Preclinical Development Update of a mRNA candidate vaccine, 15 min  Coffee Break, 30 min	Jetsumon, Mahidol University  Wanlapa Roobsong, Mahidol University  Wang Nguitragool, Mahidol University  Nawapol Kunkeaw, Mahidol University

	Consortia proposal and discussion – 1 hr 30 min <ul style="list-style-type: none"> <li>- Definition of consortia goal</li> <li>- Timelines and Budget proposal</li> <li>- Gantt Chart</li> <li>- List of members</li> <li>- Roles and Responsibilities</li> <li>- Stakeholder engagement</li> </ul>	Moderated by Jetsumon (Mahidol University)
17:00 – 18:30	<b>mRNA 4<sup>th</sup> SCIENTIFIC COLLOQUIUM</b>	Organized by MPP
18:30 – 20:30	<b>RECEPTION</b>	In Ballroom 1

**Tuesday 19 March 2024**

Time	Topic	Proposed speaker
<b>Part III – Innovations in mRNA technology</b>		
9:00 – 9:30	Development of a saRNA rotavirus candidate vaccine and non-LNP formulations: preliminary results, 15 min  Panel discussion: key innovations to advance mRNA-based applications, 15min	Robin Shattock, Imperial College London  Maria Davila, Kiat Ruxrungtham, Robin Shattock.
<b>Part IV – Establishing a mRNA R&amp;D consortia for HFMD</b>		
9:30 – 12:30	Opening remarks  Summary of key scientific and technical consideration to advance HFMD vaccine development, 30 min  Draft Target Product Profile for a mRNA HFMD vaccine, 20 min  Vaccine Design and Preclinical Development Update of a mRNA candidate vaccine, 10 min  Coffee Break  Consortia proposal and discussion – 1 hr 30 min <ul style="list-style-type: none"> <li>- Definition of consortia goal</li> <li>- Timelines and Budget proposal</li> <li>- Gantt Chart</li> <li>- List of members</li> <li>- Roles and Responsibilities</li> <li>- Stakeholder engagement</li> </ul>	Alain Bouckenooghe, Hilleman Labs  Pei-Yin Lim and Jordi Esparza, Hilleman Labs  Justin Chu/Alain Bouckenooghe  Justin Chu, National University of Singapore  Moderated by Alain Bouckenooghe Presenter: Jordi Panel: all consortia members present: Justin, Sylvie, Wan Yue, Yi Yan Yang, Boon Tong, Pei-Yin, Jordi
12.30 – 13.30	<i>Lunch Break</i>	

<b>Part V – Establishing a mRNA R&amp;D consortia for Tx HPV</b>		
13:30 – 15:30	<p>Summary of key scientific and technical consideration to advance HPV Tx vaccine development, 30 min</p> <p>Draft Target Product Profile for a mRNA HPV Tx vaccine, 20 min</p> <p>Preclinical Development Update of a mRNA candidate vaccine, 10 min</p> <p>Consortia proposal and discussion – 1 hr</p> <ul style="list-style-type: none"> <li>- Definition of consortia goal</li> <li>- Timelines and Budget proposal</li> <li>- Gantt Chart</li> <li>- List of members</li> <li>- Roles and Responsibilities</li> <li>- Stakeholder engagement</li> </ul>	<p>Kiat Ruxrungtham, Chula VRC</p> <p>Martin, WHO</p> <p>Eakachai, Supichcha, Chula VRC</p> <p>Moderated by Kiat Ruxrungtham, Chula VRC</p> <p>Panel: Petro Terblanche, Afrigen Nakorn Premsi, NVI Mainul Ahasan, Incepta Martin Friede, WHO Raman Rao, Hilleman</p>
15.30 – 16.00	<i>Coffee Break</i>	
<b>Part VI – Engagement of key regional stakeholders</b>		
16.00 – 16.10	Recap of the 4 consortia	Martin and Kiat
16.10 – 17.40	Investment opportunities for regional mRNA R&D consortia and the broader development agenda for regional vaccine manufacturing and R&D ecosystems in Asia.	<p>1<sup>st</sup> panel: Moderator:</p> <ul style="list-style-type: none"> <li>• Claudia Nannei, Senior Program Manager, WHO</li> </ul> <p>Speakers:</p> <ul style="list-style-type: none"> <li>• Hani Kim, Executive Director, RIGHT Foundation</li> <li>• Representative from the Hong Kong Jockey Club Charities Trust</li> <li>• Lee Foo Kay, Head Project Of, Temasek Foundation</li> <li>• Zurina Moktar, Assistant Director, Head of the Science &amp; Technology Division, ASEAN Secretariat</li> </ul> <p>2<sup>nd</sup> panel: Moderator:</p> <ul style="list-style-type: none"> <li>• Matthias Helble, Scientist, WHO</li> </ul> <p>Speakers:</p> <ul style="list-style-type: none"> <li>• Eduardo Banzon, Principal Health Specialist, Asian Development Bank</li> </ul>

		<ul style="list-style-type: none"><li>• Ammar Abdo Ahmed, Manager, Economic &amp; Social Infrastructure, Islamic Development Bank</li><li>• Giles Edward Newmarch, Senior Investment Officer, International Finance Corporation</li><li>• Rupa Chanda, Director, Trade, Investment and Innovation Division, UN ESCAP</li></ul>
--	--	--